Our own work with doxorubicin independently confirmed a similar effect in neuroblastoma (and to a limited extent glioblastoma also): Here we could show that posttreatment with NVP-BEZ235, a dual PI3-K/mTOR inhibitor, sensitizes cancer cells for doxorubicin-induced apoptosis to a far greater extent than co- or pretreatment [76]. The gene discussed is MTOR; the disease is neuroblastoma.